Verorab^®

a - This regimen should not e used for immuneocompromised individuals (see subsection "Immunocompromised individuals")

b - One injection in each arm (for adults and children) or each anterolateral thigh (infants and toddlers)

Booster doses are determined based on the risk of exposure and on serological tests to detect the presence of rabies virus-neutralising antibodies (≥ 0.5 IU/ml).

A booster dose consists of one dose of 0.5 mL given by intramuscular route or one dose of 0.1 mL given by intradermal route in accordance with WHO recommendations.

Verorab can be administered as a booster injection after primary vaccination with a cell culture rabies vaccine (a rabies vaccine prepared in Vero cells or prepared in human diploid cells (HDCV)).

Immunocompromised individuals:
3-dose regimen should be used and serology test done 2-4 weeks after last dose to confirm seroprotection (additional injections may be needed)

Refer to SMPC for full list of adverse reactions.

* Within each system organ class, adverse reactions are ranked under headings of frequency using the following convention: 

• very common (≥ 1/10); 
• common (≥ 1/100 and <1/10);